{"id":399946,"date":"2025-10-03T00:00:00","date_gmt":"2025-10-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0051-2025-biopharma-hidradenitis-suppurativa-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-03-31T10:24:48","modified_gmt":"2026-03-31T10:24:48","slug":"algoim0051-2025-biopharma-hidradenitis-suppurativa-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0051-2025-biopharma-hidradenitis-suppurativa-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Hidradenitis Suppurativa &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Hidradenitis Suppurativa (US)"},"content":{"rendered":"<p>Hidradenitis suppurativa (<abbr title=\"hidradenitis suppurativa\">HS<\/abbr>) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically painful and filled with fluid or pus. AbbVie\u2019s Humira (adalimumab) was the only <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved therapy for <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> until October 2023, when the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approved Cosentyx for moderate to severe <abbr title=\"hidradenitis suppurativa\">HS<\/abbr>, the same patient population for which Humira is specifically approved. Notably, depending on their specific symptoms, patients may initially receive off-label treatment with other agents, such as antibiotics and immunosuppressants, before their physician prescribes these approved biologics. Alternative targeted therapies (e.g., Johnson &#038; Johnson Innovative Medicine\u2019s Remicade [infliximab]) may be used off-label for more severe disease and for patients who do not respond to Humira or Cosentyx. This content will provide manufacturers of current treatments, as well as those developing novel <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> agents, with insights into the use of various drugs for <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> and market trends in this area.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patients?<\/li>\n<li>How has Humira been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs:<\/strong> Humira, infliximab biosimilars, Enbrel, Stelara, Simponi, clindamycin, doxycycline, acitretin, methotrexate, dapsone, cyclosporine, tacrolimus, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi, Ilumya, Cimzia<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-399946","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399946\/revisions"}],"predecessor-version":[{"id":575323,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399946\/revisions\/575323"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=399946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}